Lakewood-Amedex Biotherapeutics Inc. Common Stock
Veridion Score
Composite trend over time
Why is LABT moving today?
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for LABT.
LABT insider activity
Lakewood-Amedex Biotherapeutics Inc. Common Stock
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for LABT.
LABT contract awards, year to date.
Public federal awards linked to this ticker.
LABT lobbying filings, year to date.
Registered lobbying filings matched to Lakewood-Amedex Biotherapeutics Inc. Common Stock.